Using genomics to identify high-risk myeloma after autologous stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 12, Issue SUPPL. 1, 2006, Pages 77-80

  Shaughnessy Jr , John D ^a   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Autologous stem cell transplantation; High dose therapy; Multiple myeloma; Survival

Indexed keywords

BORTEZOMIB; CYCLIN D; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MELPHALAN; THALIDOMIDE; THALIDOMIDE DERIVATIVE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GENETICS; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 1; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG MEGADOSE; GENE ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC DISORDER; HUMAN; MULTIPLE MYELOMA; PROGNOSIS; PROTEIN INTERACTION; TREATMENT FAILURE;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; COHORT STUDIES; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PLASMA CELLS; PREDICTIVE VALUE OF TESTS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE;

EID: 29844450880     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.10.002     Document Type: Article

References (41)

1. B. Barlogie J. Shaughnessy N. Munshi J. Epstein Plasma cell myeloma in:E. Beutler M.A. Lichtman B.S. Coller T.J. Kipps V. Seligson eds Williams Hematology 6th ed. 2001 McGraw-Hill New York 1279-1304
2. J.A. Child G.J. Morgan F.E. Davies et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med. 348 2003 1875-1883
3. M. Attal J.L. Harousseau T. Facon et al. Single versus double autologous stem-cell transplantation for MM N Engl J Med. 349 2003 2495-2502
4. B. Barlogie J. Shaughnessy G. Tricot et al. Treatment of multiple myeloma Blood 103 2004 20-32
5. R. Fonseca B. Barlogie R. Bataille et al. Genetics and cytogenetics of MM: A workshop report Cancer Res. 64 2004 1546-1558
6. N.V. Smadja C. Fruchart F. Isnard et al. Chromosomal analysis in multiple myeloma: Cytogenetic evidence of two different diseases Leukemia 12 1998 960-969
7. W.M. Kuehl P.L. Bergsagel MM: Evolving genetic events and host interactions Nat Rev Cancer. 2 2002 175-187
8. J. Shaughnessy B. Barlogie Interpreting the molecular biology and clinical behavior of MM through global gene expression profiling Immunol Rev. 94 2003 140-163
9. R. Fonseca C.S. Debes-Marun E.B. Picken et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma Blood 102 2003 2562-2567
10. N.V. Smadja D. Leroux J. Soulier et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases Genes Chromosomes Cancer 38 2003 234-239
11. J.R. Sawyer J.A. Waldron S. Jagannath B. Barlogie Cytogenetic findings in 200 patients with multiple myeloma Cancer Genet Cytogenet. 82 1995 41-49
12. P. Bergsagel M. Kuehl F. Zhan J. Sawyer B. Barlogie J. Shaughnessy Cyclin D dysregulation: An early and unifying pathogenic event in MM Blood 106 2005 296-303
13. S. Wuilleme N. Robillard L. Lode et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma Leukemia 19 2005 275-278
14. F.W. Cremer J. Bila I. Buck et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics Genes Chromosomes Cancer 44 2005 194-203
15. R. Fonseca E. Blood M. Rue et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma Blood 101 2003 4569-4575
16. S. Soverini M. Cavo C. Cellini et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation Blood 102 2003 1588-1594
17. J.J. Keats T. Reiman C.A. Maxwell et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression Blood 101 2003 1520-1529
18. N.V. Smadja C. Bastard C. Brigaudeau D. Leroux C. Fruchart Hypodiploidy is a major prognostic factor in multiple myeloma Blood 98 2001 2229-2238
19. A.B. Fassas T. Spencer J. Sawyer et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma Br J Haematol. 118 2002 1041-1047
20. R. Fonseca D. Harrington M.M. Oken et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: An Eastern Cooperative Oncology Group study Cancer Res. 62 2002 715-720
21. J. Shaughnessy J. Jacobson J. Sawyer et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: Interpretation in the context of global gene expression Blood 101 2003 3849-3856
22. M.A. Gertz M.Q. Lacy A. Dispenzieri et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy Blood 106 2005 2837-2840
23. E. Tian F. Zhan R. Walker et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma N Engl J Med. 349 2003 2483-2494
24. D.F. Robbiani M. Chesi P.L. Bergsagel Bone lesions in molecular subtypes of multiple myeloma N Engl J Med. 351 2004 197-198
25. F. Zhan J. Hardin K. Bumm et al. Global gene expression profiling of MM, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells Blood 99 2002 1745-1757
26. R. Fonseca R.J. Bailey G.J. Ahmann et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance Blood 100 2002 1417-1424
27. H. Kaufmann J. Ackermann C. Baldia et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma Leukemia 18 2004 1879-1882
28. W.J. Chng S.A. Van Wier G.J. Ahmann et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS Blood 106 2005 2156-2161
29. J.R. Sawyer G. Tricot S. Mattox S. Jagannath B. Barlogie Jumping translocations of chromosome 1q in multiple myeloma: Evidence for a mechanism involving decondensation of pericentromeric heterochromatin Blood 91 1998 1732-1741
30. J.R. Sawyer G. Tricot J.L. Lukacs et al. Genomic instability in multiple myeloma: Evidence for jumping segmental duplications of chromosome arm 1q Genes Chromosomes Cancer 42 2005 95-106
31. H. Avet-Loiseau L.E. Andree-Ashley D. Moore II et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization Genes Chromosomes Cancer 19 1997 124-133
32. P. Liebisch A. Viardot N. Bassermann et al. Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma Br J Haematol. 122 2003 193-201
33. T. Nilsson M. Hoglund S. Lenhoff et al. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences Br J Haematol. 120 2003 960-969
34. N.C. Gutierrez J.L. Garcia J.M. Hernandez et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in MM Blood 104 2004 2661-2666
35. P. Le Baccon D. Leroux C. Dascalescu et al. Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma Genes Chromosomes Cancer 32 2001 250-264
36. D. Ganoth G. Bornstein T.K. Ko et al. The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27 Nat Cell Biol. 3 2001 321-324
37. C. Spruck H. Strohmaier M. Watson et al. A CDK-independent function of mammalian Cks1: Targeting of SCFSkp2 to the CDK inhibitor CDKN1B Mol Cell 7 2001 639-650
38. C.J. Sherr J.M. Roberts CDK inhibitors: Positive and negative regulators of G1-phase progression Genes Dev. 13 1999 1501-1512
39. J. Bloom M. Pagano Deregulated degradation of the cdk inhibitor p27 and malignant transformation Semin Cancer Biol. 13 2003 41-47
40. Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma Clin Cancer Res. 9 2003 820-826
41. M. Pagano R. Benmaamar When protein destruction runs amok, malignancy is on the loose Cancer Cell 4 2003 251-256